Rubicon Organics Inc (TSE:ROMJ)
:ROMJ
Want to see TSE:ROMJ full AI Analyst Report?
Top Page
Rubicon Organics
(ROMJ)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.45
▼(-4.04% Downside)
Action:Reiterated
Date:05/15/26
The score is held back primarily by weak financial quality—recent return to losses and meaningful cash burn—alongside bearish technicals with the price below major moving averages. Valuation is difficult to assess due to negative earnings and no dividend support, providing limited offset.
Positive Factors
Certified-organic CPG focus
Rubicon’s certified-organic positioning creates a durable product differentiation in Canada’s regulated adult-use CPG channel. A clear niche can support premium pricing, brand loyalty, and retail placement advantages versus commodity producers, strengthening long-term revenue quality.
Negative Factors
Deteriorating cash generation
Negative operating cash flow and deeply negative free cash flow increase reliance on external funding and heighten dilution or refinancing risk. Persistently poor cash conversion limits ability to self-fund growth, capex, or cushion margin shocks over multi-quarter horizons.
Read all positive and negative factors
Positive Factors
Negative Factors
Certified-organic CPG focus
Rubicon’s certified-organic positioning creates a durable product differentiation in Canada’s regulated adult-use CPG channel. A clear niche can support premium pricing, brand loyalty, and retail placement advantages versus commodity producers, strengthening long-term revenue quality.
Read all positive factors
Rubicon Organics (ROMJ) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$29.22M
Dividend YieldN/A
Average Volume (3M)65.53K
Price to Earnings (P/E)―
Beta (1Y)0.02
Revenue Growth16.45%
EPS Growth-6.36%
CountryCA
Employees208
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding67,175,770
10 Day Avg. Volume72,944
30 Day Avg. Volume65,526
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)0.71
Price to Sales (P/S)0.53
P/FCF Ratio-2.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$1.15Price Target Upside144.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.01
Revenue Forecast (FY)C$72.07M
Rubicon Organics Business Overview & Revenue Model
Company Description
Rubicon Organics Inc. produces and sells organic cannabis for the recreational and medical-use markets in Canada. The company processes and sells organic cannabis under its wholly owned and other licensed brands. Rubicon Organics Inc. was incorpor...
How the Company Makes Money
Rubicon Organics makes money primarily by selling regulated cannabis products into the Canadian adult-use (recreational) market. Its core revenue stream is wholesale and/or direct-to-board sales of packaged cannabis (notably dried flower, and othe...
Rubicon Organics Earnings Call Summary
Earnings Call Date:Aug 18, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Aug 13, 2026
Earnings Call Sentiment Positive
Rubicon Organics demonstrated strong performance in Q2 2025 with record-breaking revenue growth, improved gross margins, and positive cash flow. Strategic expansion and innovation in product offerings indicate a solid position for future growth. However, the company faces challenges with share erosion in topicals, licensing delays for a new facility, and inventory management.Positive Updates
Record-Breaking Revenue and Growth
Rubicon Organics delivered a record net revenue of $15 million in Q2 2025, marking the highest ever for a single quarter, up 24% year-over-year and 21% sequentially.
Negative Updates
Share Erosion in Topicals
Experienced some share erosion in the topical category with competitors entering the market with more SKUs at lower price points.
Read all updates
Q2-2025 Updates
Positive
Negative
Record-Breaking Revenue and Growth
Rubicon Organics delivered a record net revenue of $15 million in Q2 2025, marking the highest ever for a single quarter, up 24% year-over-year and 21% sequentially.
Read all positive updates
Company Guidance
During Rubicon Organics' Q2 2025 earnings call, the company reported record net revenue of $15 million, marking a 24% increase year-over-year and a 21% sequential rise. Gross profit reached $5.9 million with a gross margin of 34%, up from 30% the previous year. Adjusted EBITDA was $1.4 million, contributing to a year-to-date total of $2.1 million. The company's growth was driven by its expanding 1964 brand, particularly in the pre-roll and vape segments, which saw a significant increase in SKUs and captured over 15% of the market. Rubicon also maintained a strong presence in premium edibles and topicals, holding the #1 position in premium edibles and #2 in topicals. The company completed a $4.5 million private placement and finalized the acquisition of its Hope facility to increase production capacity by 40%, positioning itself for further growth amid a global cannabis supply shortage. Rubicon closed the quarter with $7.3 million in cash and $18.7 million in working capital, supported by disciplined cost control and a prudent capital structure.Rubicon Organics Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
67
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.76M | 59.45M | 48.70M | 40.12M | 35.52M | 22.61M |
| Gross Profit | 12.75M | 22.14M | 15.42M | 13.14M | 13.81M | 1.51M |
| EBITDA | -1.71M | 5.12M | 1.86M | 2.40M | 217.00K | -10.87M |
| Net Income | -1.38M | 1.05M | -2.56M | -1.82M | -3.86M | -14.52M |
Balance Sheet | ||||||
| Total Assets | 66.05M | 66.89M | 56.61M | 54.89M | 56.11M | 54.84M |
| Cash, Cash Equivalents and Short-Term Investments | 3.20M | 3.99M | 9.86M | 10.91M | 8.29M | 11.58M |
| Total Debt | 13.43M | 12.42M | 9.89M | 10.40M | 10.22M | 9.82M |
| Total Liabilities | 24.41M | 22.84M | 19.21M | 17.00M | 17.77M | 15.94M |
| Stockholders Equity | 41.64M | 44.06M | 37.40M | 37.89M | 38.33M | 38.90M |
Cash Flow | ||||||
| Free Cash Flow | -10.21M | -12.04M | 1.85M | 2.32M | -2.50M | -15.94M |
| Operating Cash Flow | -253.93K | -3.63M | 3.40M | 5.05M | 1.95M | -10.44M |
| Investing Cash Flow | -9.95M | -8.42M | -1.55M | -2.73M | -4.45M | -5.50M |
| Financing Cash Flow | 5.71M | 6.25M | -1.77M | -804.01K | -838.56K | 15.30M |
Rubicon Organics Technical Analysis
Negative
0.47
Price Trends
0.51
Negative
0.49
Negative
0.51
Negative
Market Momentum
-0.01
Positive
32.36
Neutral
24.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ROMJ, the sentiment is Negative. The current price of 0.47 is below the 20-day moving average (MA) of 0.51, below the 50-day MA of 0.51, and below the 200-day MA of 0.51, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 32.36 is Neutral, neither overbought nor oversold. The STOCH value of 24.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ROMJ.
Rubicon Organics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | C$9.29M | 8.94 | 11.57% | ― | -6.27% | 61.54% | |
56 Neutral | C$33.99M | -8.58 | -19.10% | ― | 0.66% | -14.29% | |
53 Neutral | C$15.39M | 5.19 | ― | ― | -25.05% | 67.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$22.49M | 2.74 | -71.80% | ― | -7.53% | 41.77% | |
46 Neutral | C$29.22M | -3.14 | 7.78% | ― | 16.45% | -6.36% | |
46 Neutral | C$16.35M | -7.68 | -68.32% | ― | 1.96% | -24.60% |
* Healthcare Sector Average
TSE:ROMJ
Rubicon Organics
0.44
0.02
3.57%
TSE:LABS
MediPharm Labs
0.08
<0.01
14.29%
TSE:PCLO
PharmaCielo
0.10
0.05
100.00%
TSE:OILS
Nextleaf Solutions
0.06
>-0.01
-8.33%
TSE:AVCN
Avicanna
0.13
-0.15
-53.57%
TSE:INNO
InnoCan Pharma
5.00
-5.40
-51.92%
Rubicon Organics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Rubicon Organics’ 1964 Supply Co. Enters U.K. Medical Cannabis Market via 4C LABS
Positive
Apr 13, 2026
Rubicon Organics has launched its award-winning 1964 Supply Co. medical cannabis brand in the United Kingdom through a distribution partnership with 4C LABS, marking the brand’s first international route-to-market. The move expands the compa...
Business Operations and Strategy
Rubicon Organics Targets Global Premium Cannabis Growth With European Conference Push
Positive
Apr 9, 2026
Rubicon Organics, a leading Canadian producer of certified organic premium cannabis, is expanding its footprint through a house of high-performing brands and a vertically integrated platform anchored by two cultivation facilities in British Columb...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Rubicon Organics Posts Record 2025 Results and Scales Up Premium Cannabis Capacity
Positive
Mar 24, 2026
Rubicon Organics reported record 2025 net revenue of $59.5 million, up 22% year over year, with adjusted EBITDA rising to $5.0 million and operations turning from a loss to a $1.8 million profit. The company strengthened its balance sheet with new...
Business Operations and StrategyFinancial Disclosures
Rubicon Organics Delivers Record 2025 Results and Ramps Up Cascadia Facility
Positive
Mar 24, 2026
Rubicon Organics reported record 2025 net revenue of $59.5 million, up 22% from 2024, with gross profit before fair value adjustments rising 27% to $19.5 million and adjusted EBITDA reaching $5.0 million. The company generated $1.8 million in inco...
Business Operations and StrategyFinancial Disclosures
Rubicon Organics Sets Date to Report Q4 2025 Results Amid Capacity Expansion
Positive
Mar 10, 2026
Rubicon Organics will release its financial results for the fourth quarter and full year ended December 31, 2025 after markets close on March 23, 2026, followed by a conference call and webcast the next day to discuss its performance. The timing o...
Business Operations and Strategy
Rubicon Organics Boosts Premium Cannabis Output with Cascadia Facility Launch
Positive
Feb 19, 2026
Rubicon Organics has completed the first harvest at its new Cascadia facility in Hope, B.C., marking a key operational milestone in expanding its premium cannabis production base. The 47,500-square-foot indoor site is fully planted and is estimate...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.